Introduction {#Sec1}
============

Diffuse large B cell lymphoma (DLBCL) is the most common aggressive form of non-Hodgkin's lymphoma. Combination chemotherapy with rituximab is initially administered to most newly diagnosed patients with DLBCL \[[@CR1]--[@CR4]\]. However, if the patients relapse after the initial chemotherapy, their lymphoma can be poorly managed because most DLBCL cases ultimately become chemotherapy-resistant unless treated with high-dose chemotherapy with autologous stem cell transplantation (ASCT) \[[@CR5], [@CR6]\]. Instead of combination chemotherapy with rituximab, other treatments including more intensive chemotherapy, up-front ASCT after the first remission, or other newly developed drugs are required to improve survival of the patients who are at high risk of relapse \[[@CR7], [@CR8]\]. Therefore, defining prognostic factors that can easily and accurately classify patients with untreated DLBCL into appropriate risk groups for relapse is highly important for disease management.

Although ^18^F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging for DLBCL have been widely utilized to evaluate the staging and residual lesions after treatment with high sensitivity \[[@CR9]--[@CR12]\], the relevance of the maximum standard uptake value (SUV~max~) in this technique to disease outcome has been poorly studied. The SUV~max~ at the biopsy site of non-Hodgkin's lymphoma patients has been reported to correlate with the proliferation potential \[[@CR13]\]. Anecdotal cases from our hospital (unpublished) also suggest that patients with low SUV~max~ DLBCL before treatment are more likely to remain in remission, while those with high SUV~max~ DLBCL are more likely to relapse. However, this idea has not been confirmed by a systematic analysis of clinical cases. Therefore, in this study, we retrospectively analyzed 50 patients with DLBCL in order to examine the relationship between the initial SUV~max~ of FDG-PET and disease progression.

Patients and methods {#Sec2}
====================

Eligibility criteria {#Sec3}
--------------------

In this study, patients with de novo DLBCL, excluding those with transformation from indolent lymphoma, diagnosed between April 2006 and December 2009 at Ehime Prefectural Central Hospital (Matsuyama, Japan) were retrospectively analyzed. FDG-PET imaging was performed in all patients before the treatment, and the SUV~max~ at the primary lesion was measured. The patients subsequently received combination chemotherapy with rituximab. Patients whose primary lesions were excised surgically before FDG-PET imaging or who were treated palliatively, including only radiotherapy or only rituximab, were excluded from this study. The observation period was from April 2006 to March 2011.

PET/CT acquisition and processing {#Sec4}
---------------------------------

FDG-PET/CT imaging was performed using a multi-slice PET/CT camera (Discovery STE with 16-slice CT; GE Healthcare). All patients had fasted for a minimum of 6 h, with a blood glucose level of 80--120 mg/dL before intravenous administration of ^18^F-FDG. A whole-body image was obtained exactly 60 min after the intravenous administration of 222--370 MBq (6--10 mCi) of ^18^F-FDG. The PET emission images were corrected for measured attenuation and reconstructed using an ordered-subset expectation maximization iterative algorithm per the manufacturer's instructions. Integrated PET and CT images were reviewed on Advantage Workstations (GE Healthcare). Display field of view was 60 × 60 cm, which consisted of 192 × 192 matrixes, on the display. Voxel size was 3.125 × 3.125 × 3.27 mm^3^. For each PET data set, in patients with multiple lesions, the tumor with the most intense FDG uptake among all foci was identified by the maximal counts. A volumetric region of interest was approximately 8 cm^3^ (250 voxels) or more and set on the axial fusion images of PET and CT to calculate SUV~max~. A volumetric region of interest encompassing the entire tumor was drawn to ensure correct identification of the maximal counts, and the SUV~max~ was calculated.

Treatment {#Sec5}
---------

All patients received rituximab-containing combination chemotherapy as an initial treatment. The cyclophosphamide, doxorubicin, vincristine, and prednisolone with rituximab (R-CHOP) regimen was administered to younger patients (\<70 years old) with DLBCL, and the pirarubicin, cyclophosphamide, vincristine, and prednisolone with rituximab (R-THPCOP) regimen was administered to elderly patients (≥70 years old). Most patients with advanced-stage disease, defined as Ann Arbor stages III or IV, or stage I and II with bulky disease (≥10 cm), received six to eight cycles of R-CHOP or R-THPCOP every 21 days. Only the patients who had Ann Arbor stages I and II without bulky disease received three cycles of R-CHOP or R-THPCOP and field radiation therapy. Complete remission (CR) was defined by FDG-PET scan according to the recently published criteria \[[@CR9]\]. All relapsed patients received salvage chemotherapy, and ASCT was performed in eligible cases.

Statistical analysis {#Sec6}
--------------------

Overall survival (OS) was defined as the time from the start of chemotherapy to death from any cause. Progression-free survival (PFS) was defined as the time from the start of chemotherapy to relapse or death. The Mann--Whitney *U* test was used to calculate the differences between two groups. The probabilities of OS and PFS were estimated by the Kaplan--Meier method. The association of various factors with the hazards of failure for the time-to-endpoint PFS was estimated using the Cox proportional hazard regression model. A *P* value of \<0.05 was considered statistically significant. SPSS version 17.0 was used for all analyses.

Results {#Sec7}
=======

Patients and characteristics {#Sec8}
----------------------------

Fifty patients who met the eligibility criteria were analyzed. Clinical characteristics including International Prognostic Index (IPI) factors \[[@CR14]\], revised IPI (R-IPI) \[[@CR15]\], and the individual treatments are listed in Table [1](#Tab1){ref-type="table"}. Most patients (90 %) received six to eight cycles of R-CHOP or R-THPCOP. Other patients (10 %) received three cycles of R-CHOP or R-THPCOP and field radiation therapy. No patients underwent up-front ASCT after R-CHOP or R-THPCOP. All patients experiencing refractory and relapsed DLBCL (*n* = 26) were treated with salvage chemotherapy, and seven patients (27 %) who achieved complete or partial response and were 70 years old or younger underwent ASCT with high-dose chemotherapy.Table 1Patients characteristicsAll (*n* = 50)Low SUV~max~ (*n* = 10)High SUV~max~ (*n* = 40)*P* valueMedian SUV~max~ (range)21.0 (8.2--47.1)11.4 (8.2--14.7)22.1 (15.0--47.1)\<0.001Median age (range)66 (41--85)63 (49--82)67 (41--85)0.280Male/female32/184/628/120.080IPI factors Age \>60 years378290.632 PS \>1161150.099 LDH \>normal325270.307 Extranodal site \>1164120.548 Stage III/IV316250.885DLBCL subgroup/subtype NOS421032 THRLBCL202 PCDLBCL404 PMBL202IPI H/I, H305250.475Revised IPI0.431 Very good523 Good16313 Poor29524Bulky mass5050.243sIL-2R \>normal397320.499Primary lesion0.401 LNs24618 Others26422Treatment0.161 R-CHOP36927 R-THPCOP14113Complete remission399300.311Recurrence261250.003Alive/death38/129/129/110.251*SUV*~*max*~ maximum standardized uptake value, *IPI* International Prognostic Index, *PS* Eastern Cooperative Oncology Group Performance Status, *LDH* lactate dehydrogenase, *DLBCL* diffuse large B cell lymphoma, *NOS* not otherwise specified, *THRLBCL* T cell/histiocyte-rich large B cell lymphoma, *PCDLBCL* primary cutaneous diffuse large B cell lymphoma, *PMBL* primary mediastinal large B cell lymphoma, *sIL*-*2R* soluble interleukin-2 receptor, *LNs* lymph nodes, *R*-*CHOP* cyclophosphamide, doxorubicin, vincristine, and prednisolone with rituximab, *R*-*THPCOP* pirarubicin, cyclophosphamide, vincristine, and prednisolone with rituximab

The patients were first divided into two prognostic factor groups at various (10, 15, 20, 25, 30, or 35) in order to determine the appropriate cutoff point, and then OS and PFS were analyzed. Although OS curves were not significantly different between each pair of groups for all cutoff values, PFS curves were significantly higher in patients with the SUV~max~ \<15 than in those with the SUV~max~ ≥15. Other cutoff values for PFS curves were not statistically significant. Thus, we determined that the SUV~max~ cutoff value should be 15 in this study.

Univariate and multivariate analysis of OS and PFS for patients with low- and high SUV~max~ {#Sec9}
-------------------------------------------------------------------------------------------

The median follow-up time was 32.7 months (range, 4.8--58.3 months). Patients with SUV~max~ \<15 (low SUVmax) (*n* = 10) and those with SUV~max~ ≥15 (high SUV~max~) (*n* = 40) had similar backgrounds regarding age, sex, IPI factors, IPI classification, R-IPI classification, and individual treatment (Table [1](#Tab1){ref-type="table"}). The CR rate of all patients was 78 %. CR rates of patients with low SUV~max~ and those with high SUV~max~ were 90 and 75 %, respectively (*P* = 0.311). However, patients with low SUV~max~ had a significantly lower recurrence rate than that of those with high SUV~max~ values (*P* = 0.003).

The 3-year OS rates for patients with low SUV~max~ and for those with high SUV~max~ were 90 and 72 %, respectively (*P* = 0.255) (Fig. [1a](#Fig1){ref-type="fig"}). The 3-year PFS rate in each group was 90 and 39 %, respectively (*P* = 0.012) (Fig. [1b](#Fig1){ref-type="fig"}). While no factors could predict OS, multivariate analysis of PFS showed that the R-IPI \[hazard ratio (HR) 3.37 (1.35--8.39), *P* = 0.009\] and low SUV~max~ \[HR 7.49 (1.00--55.95), *P* = 0.049\] were good independent prognostic factors (Table [2](#Tab2){ref-type="table"}).Fig. 1OS (**a**) and PFS (**b**) based on SUV~max~Table 2Multivariate analysis of risk factors for OS and PFSOSPFSHR(95 % CI)*P*HR(95 % CI)*P*Revised IPI1.92(0.58--6.36)0.2873.37(1.35--8.39)0.009Low SUV~max~2.51(0.31--20.03)0.3857.49(1.00--55.95)0.049Bulky mass1.02(0.21--4.99)0.9791.29(0.37--4.51)0.693sIL-2R \>normal2.31(0.27--19.42)0.4410.85(0.27--2.67)0.775Primary lesions except LNs1.49(0.42--5.23)0.5331.01(0.44--2.29)0.988*OS* overall survival, *PFS* progression-free survival, *HR* hazard ratio, *95 % CI* 95 % confidence interval, *IPI* International Prognostic Index, *SUV*~*max*~ maximum standardized uptake value, *sIL*-*2R* soluble interleukin-2 receptor, *LNs* lymph nodes

Analysis of R-IPI combined with SUV~max~ {#Sec10}
----------------------------------------

According to the R-IPI categories, all patients in this study were divided into prognosis groups of "very good" (*n* = 5), "good" (*n* = 16), and "poor" (*n* = 29), and the 3-year OS and PFS for each group were 100, 81, and 68 % (*P* = 0.167) and 100, 69, and 29 % (*P* = 0.016) (Fig. [2a](#Fig2){ref-type="fig"}), respectively. In the very good prognosis group, no patients had a recurrence of DLBCL. In the good prognosis group, the 3-year OS and PFS for patients with low SUV~max~ and those with high SUV~max~ were 100 and 77 % (*P* = 0.386) and 100 and 62 % (*P* = 0.161), respectively (Fig. [2b](#Fig2){ref-type="fig"}). In the poor prognosis group, the 3-year OS and PFS for patients with low SUV~max~ and those with high SUV~max~ were 80 and 68 % (*P* = 0.549) and 80 and 18 % (*P* = 0.050), respectively (Fig. [2c](#Fig2){ref-type="fig"}).Fig. 2PFS of all patients divided into "very good," "good," and "poor" prognosis groups by R-IPI (**a**), of patients in the "good" prognosis group according to SUV~max~ (**b**), and of patients in the "poor" prognosis group according to SUV~max~ (**c**)

Discussion {#Sec11}
==========

A relatively higher proportion of patients administered initial chemotherapy including rituximab have been shown to be successfully treated and remain in remission from newly diagnosed DLBCL, compared with those receiving no rituximab \[[@CR1]--[@CR4]\], but a large number of patients still undergo relapses. Treatment strategies other than R-CHOP are either initially more intensive chemotherapy or high-dose chemotherapy followed by up-front ASCT or newly developed drug. More useful prognostic factors are clearly required to identify patients with poorly managed DLBCL. However, most cytological or pathological prognostic factors for patients with DLBCL, such as bcl-2, bcl-6, CD5, CD10, and MUM-1 \[[@CR16]--[@CR18]\], are relatively expensive or time-consuming to implement for general clinical practice, since those measurements can be performed only at specific hospitals or external laboratories.

Our results indicate that the SUV~max~ of FDG-PET in the primary diagnosis of DLBCL is an important predictor of progression after the initial treatment, especially for patients categorized into the poor prognostic group by R-IPI. Furthermore, most patients with low SUV~max~ or categorized into the very good prognostic group by R-IPI sustained CR only with R-CHOP or R-THPCOP therapy. The SUV~max~ has been reported to correlate with the MIB-1 labeling index (i.e., proliferation potential), a known prognostic factor in DLBCL patients treated with R-CHOP \[[@CR13], [@CR19]\]. Therefore, DLBCL patients with low SUV~max~ appear to progress more slowly and had better prognosis than those with high SUV~max~. FDG-PET imaging for DLBCL can be used not only for staging but also for predicting the progression after treatment, and the SUV~max~ is highly useful, since it can be measured much more easily and quickly than cytological or specific pathological examinations.

Chihara et al. reported an association between high SUV~max~ on FDG-PET with shorter overall survival in patients with DLBCL \[[@CR20]\]. Their conclusions were remarkably similar to ours, while the SUV~max~ cutoff value of 30 in their study differed greatly from that of 15 in our study. The PET/CT camera, incorporation time, and treatment were the same between the two studies. However, more good prognostic patients and fewer poor prognostic patients classified by the IPI score (probably due to patients with SUV~max~ values of 15--30) were included in their report than in our study. Determination of the SUV~max~ cutoff value was likely affected by individual patient characteristics or the number of cases at the different institutes. Therefore, a multicenter analysis may be required in order to define the appropriate SUV~max~ cutoff value.

Collectively, our results suggest that the SUV~max~ on FDG-PET for newly diagnosed patients with DLBCL is an important predictor of PFS. A future prospective study to confirm our results would be of interest.
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